Axis Mutual FundEquity Scheme - Mid Cap Fund13.8 years
The scheme seeks to achieve long term capital appreciation by investing predominantly in equity & equity related instruments of Mid Cap companies.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Three-year return is above the category median.
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer Baroda BNP Paribas Mid Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.80% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -29.4%. Ask whether you can hold through a similar fall.
Vs category
Watch
41% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Krishnaa Narayan · 2.7 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 31.7% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 29%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
20 Feb 2020 – 26 Aug 2020
Trough 23 Mar 2020 · recovered in 156 days
-29.4%
5 Aug 2015 – 30 Mar 2017
Trough 26 Feb 2016 · recovered in 398 days
-25.0%
15 Jan 2013 – 24 Dec 2013
Trough 3 Sept 2013 · recovered in 112 days
-22.0%
18 Oct 2021 – 6 Jun 2023
Trough 20 Jun 2022 · recovered in 351 days
-20.3%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
82
Vs category
77
Consistency
45
Risk-adjusted
66
Drawdown
27
Mean
59
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
No status reasons yet. History is still thin.
Supporting reads
30 Sept 2026 · 87 holdings · top 10 are 31.7%.
Others CBLO
Unspecified
8.0%
The Federal Bank Ltd
Financial
4.0%
Apar Industries Ltd
Diversified
2.8%
Sona BLW Precision Forgings Ltd
Consumer Discretionary
2.7%
Fortis Healthcare Ltd
Healthcare
2.6%
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Baroda BNP Paribas Mutual Fund
Caveat: Lower trailing returns
ITI Mutual Fund
Caveat: Higher volatility · Higher TER
Edelweiss Mutual Fund
Caveat: Higher volatility · Deeper drawdown
LIC Mutual Fund
Caveat: Higher volatility · Higher TER · Lower trailing returns
Sundaram Mutual Fund
Caveat: Higher volatility · Deeper drawdown · Higher TER
Axis Mutual FundEquity Scheme - Mid Cap Fund13.8 years
The scheme seeks to achieve long term capital appreciation by investing predominantly in equity & equity related instruments of Mid Cap companies.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Three-year return is above the category median.
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer Baroda BNP Paribas Mid Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.80% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -29.4%. Ask whether you can hold through a similar fall.
Vs category
Watch
41% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Krishnaa Narayan · 2.7 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 31.7% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 29%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
30 Oct 2026 · +1.3% over 1Y
136.47
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
30 Oct 2026
-6.5%
20 Feb 2020 – 26 Aug 2020
Trough 23 Mar 2020 · recovered in 156 days
-29.4%
5 Aug 2015 – 30 Mar 2017
Trough 26 Feb 2016 · recovered in 398 days
-25.0%
15 Jan 2013 – 24 Dec 2013
Trough 3 Sept 2013 · recovered in 112 days
-22.0%
18 Oct 2021 – 6 Jun 2023
Trough 20 Jun 2022 · recovered in 351 days
-20.3%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
82
Vs category
77
Consistency
45
Risk-adjusted
66
Drawdown
27
Mean
59
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
No status reasons yet. History is still thin.
Supporting reads
30 Sept 2026 · 87 holdings · top 10 are 31.7%.
Others CBLO
Unspecified
8.0%
The Federal Bank Ltd
Financial
4.0%
Apar Industries Ltd
Diversified
2.8%
Sona BLW Precision Forgings Ltd
Consumer Discretionary
2.7%
Fortis Healthcare Ltd
Healthcare
2.6%